Matthias Guckenberger1, Rainer J Klement2, Michael Allgäuer3, Nicolaus Andratschke4, Oliver Blanck5, Judit Boda-Heggemann6, Karin Dieckmann7, Marciana Duma8, Iris Ernst9, Ute Ganswindt10, Peter Hass11, Christoph Henkenberens12, Richard Holy13, Detlef Imhoff14, Henning K Kahl15, Robert Krempien16, Fabian Lohaus17, Ursula Nestle18, Meinhard Nevinny-Stickel19, Cordula Petersen20, Sabine Semrau21, Jan Streblow22, Thomas G Wendt23, Andrea Wittig24, Michael Flentje25, Florian Sterzing22. 1. Department of Radiation Oncology, University of Wuerzburg, Germany; Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland. 2. Department of Radiation Oncology, Leopoldina Hospital Schweinfurt, Germany. 3. Department of Radiation Oncology, Barmherzige Brüder, Regensburg, Germany. 4. Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland; Department of Radiation Oncology, University Medicine Rostock, Germany. 5. Department of Radiation Oncology, UKSH Universitätsklinikum Schleswig-Holstein, Kiel, Germany. 6. Department of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, Germany. 7. Department of Radiation Oncology, Allgemeines Krankenhaus Wien, Vienna, Austria. 8. Department of Radiation Oncology, Technical University Munich, Germany. 9. Department of Radiation Oncology, Universitätsklinikum Münster, Germany. 10. Department of Radiation Oncology, LMU München, Munich, Germany. 11. Department of Radiation Oncology, Universitätsklinikum Magdeburg, Germany. 12. Department of Radiotherapy and Special Oncology, Medical School Hannover, Germany. 13. Department of Radiation Oncology, Universitätsklinikum Aachen, Germany. 14. Department of Radiation Oncology, Universitätsklinikum Frankfurt am Main, Germany. 15. Department of Radiation Oncology, Klinikum Augsburg, Germany. 16. Department of Radiation Oncology, Helios Klinikum Berlin Buch, Germany. 17. Department of Radiation Oncology, Medical Faculty and University Hospital C.G. Carus, Technische Universität Dresden, Germany. 18. Department of Radiation Oncology Universitätsklinikum Freiburg, Germany. 19. Department of Therapeutic Radiology and Oncology, Innsbruck Medical University, Austria. 20. Department of Radiation Oncology, Universitätsklinikum Eppendorf, Hamburg, Germany. 21. Department of Radiation Oncology, Friedrich Alexander University of Erlangen-Nurenberg, Germany. 22. Department of Radiation Oncology, Heidelberg University Hospital, Germany. 23. Department of Radiation Oncology, University Hospital Jena, Germany. 24. Department of Radiotherapy and Radiation Oncology, Pilipps-University Marburg, Germany. 25. Department of Radiation Oncology, University of Wuerzburg, Germany.
Abstract
BACKGROUND AND PURPOSE: To evaluate whether local tumor control probability (TCP) in stereotactic body radiotherapy (SBRT) varies between lung metastases of different primary cancer sites and between primary non-small cell lung cancer (NSCLC) and secondary lung tumors. MATERIALS AND METHODS: A retrospective multi-institutional (n=22) database of 399 patients with stage I NSCLC and 397 patients with 525 lung metastases was analyzed. Irradiation doses were converted to biologically effective doses (BED). Logistic regression was used for local tumor control probability (TCP) modeling and the second-order bias corrected Akaike Information Criterion was used for model comparison. RESULTS: After median follow-up of 19 months and 16 months (n.s.), local tumor control was observed in 87.7% and 86.7% of the primary and secondary lung tumors (n.s.), respectively. A strong dose-response relationship was observed in the primary NSCLC and metastatic cohort but dose-response relationships were not significantly different: the TCD90 (dose to achieve 90% TCP; BED of maximum planning target volume dose) estimates were 176 Gy (151-223) and 160 Gy (123-237) (n.s.), respectively. The dose-response relationship was not influenced by the primary cancer site within the metastatic cohort. CONCLUSIONS: Dose-response relationships for local tumor control in SBRT were not different between lung metastases of various primary cancer sites and between primary NSCLC and lung metastases.
BACKGROUND AND PURPOSE: To evaluate whether local tumor control probability (TCP) in stereotactic body radiotherapy (SBRT) varies between lung metastases of different primary cancer sites and between primary non-small cell lung cancer (NSCLC) and secondary lung tumors. MATERIALS AND METHODS: A retrospective multi-institutional (n=22) database of 399 patients with stage I NSCLC and 397 patients with 525 lung metastases was analyzed. Irradiation doses were converted to biologically effective doses (BED). Logistic regression was used for local tumor control probability (TCP) modeling and the second-order bias corrected Akaike Information Criterion was used for model comparison. RESULTS: After median follow-up of 19 months and 16 months (n.s.), local tumor control was observed in 87.7% and 86.7% of the primary and secondary lung tumors (n.s.), respectively. A strong dose-response relationship was observed in the primary NSCLC and metastatic cohort but dose-response relationships were not significantly different: the TCD90 (dose to achieve 90% TCP; BED of maximum planning target volume dose) estimates were 176 Gy (151-223) and 160 Gy (123-237) (n.s.), respectively. The dose-response relationship was not influenced by the primary cancer site within the metastatic cohort. CONCLUSIONS: Dose-response relationships for local tumor control in SBRT were not different between lung metastases of various primary cancer sites and between primary NSCLC and lung metastases.
Authors: Davide Franceschini; Ciro Franzese; Fiorenza De Rose; Pierina Navarria; Giuseppe R D'Agostino; Tiziana Comito; Angelo Tozzi; Maria C Tronconi; Lorenza Di Guardo; Michele Del Vecchio; Marta Scorsetti Journal: Br J Radiol Date: 2017-07-14 Impact factor: 3.039
Authors: Christos Moustakis; Oliver Blanck; Fatemeh Ebrahimi; Mark Ka Heng Chan; Iris Ernst; Thomas Krieger; Marciana-Nona Duma; Markus Oechsner; Ute Ganswindt; Christian Heinz; Horst Alheit; Hilbert Blank; Ursula Nestle; Rolf Wiehle; Christine Kornhuber; Christian Ostheimer; Cordula Petersen; Gerhard Pollul; Wolfgang Baus; Georg Altenstein; Eric Beckers; Katrin Jurianz; Florian Sterzing; Matthias Kretschmer; Heinrich Seegenschmiedt; Torsten Maass; Stefan Droege; Ulrich Wolf; Juergen Schoeffler; Uwe Haverkamp; Hans Eich; Matthias Guckenberger Journal: Strahlenther Onkol Date: 2017-09-15 Impact factor: 3.621
Authors: Susanne Stera; Panagiotis Balermpas; Mark K H Chan; Stefan Huttenlocher; Stefan Wurster; Christian Keller; Detlef Imhoff; Dirk Rades; Jürgen Dunst; Claus Rödel; Guido Hildebrandt; Oliver Blanck Journal: Strahlenther Onkol Date: 2017-09-05 Impact factor: 3.621
Authors: Susanne Temming; Martin Kocher; Erich Stoelben; Lars Hagmeyer; De-Hua Chang; Konrad Frank; Khosro Hekmat; Juergen Wolf; Wolfgang W Baus; Robert Semrau; Christian Baues; S Marnitz Journal: Strahlenther Onkol Date: 2017-08-15 Impact factor: 3.621
Authors: Rohan R Katipally; Sean P Pitroda; Aditya Juloori; Steven J Chmura; Ralph R Weichselbaum Journal: Nat Rev Clin Oncol Date: 2022-07-12 Impact factor: 65.011
Authors: Christos Moustakis; Oliver Blanck; Fatemeh Ebrahimi Tazehmahalleh; Mark Ka Heng Chan; Iris Ernst; Thomas Krieger; Marciana-Nona Duma; Markus Oechsner; Ute Ganswindt; Christian Heinz; Horst Alheit; Hilbert Blank; Ursula Nestle; Rolf Wiehle; Christine Kornhuber; Christian Ostheimer; Cordula Petersen; Gerhard Pollul; Wolfgang Baus; Georg Altenstein; Eric Beckers; Katrin Jurianz; Florian Sterzing; Matthias Kretschmer; Heinrich Seegenschmiedt; Torsten Maass; Stefan Droege; Ulrich Wolf; Juergen Schoeffler; Uwe Haverkamp; Hans Theodor Eich; Matthias Guckenberger Journal: Strahlenther Onkol Date: 2017-05-31 Impact factor: 3.621
Authors: Juliane Hoerner-Rieber; Marciana Duma; Oliver Blanck; Guido Hildebrandt; Andrea Wittig; Fabian Lohaus; Michael Flentje; Frederick Mantel; Robert Krempien; Michael J Eble; Klaus Henning Kahl; Judit Boda-Heggemann; Stefan Rieken; Matthias Guckenberger Journal: J Thorac Dis Date: 2017-11 Impact factor: 2.895